Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) Bundle
Founded in Hefei on September 28, 2000, Anhui Anke Biotechnology Co., Ltd. (listed as 300009.SZ) has grown from a regional biopharma startup to a publicly traded group that entered ChiNext in 2009, reported ¥1.1 billion in revenue and ¥278 million net profit in 2017 (up 29.09% and 40.77% year‑on‑year respectively), expanded its pipeline with a $50 million monoclonal antibody acquisition in 2022, and in 2024 secured a licensing deal to use Shanghai Escugen's ADC platform EZWi‑Fit® while operating GMP facilities, national technology centers, and a sales network across more than 30 provinces; its ownership mix includes founder‑chairman Du Zhenghua as the largest shareholder plus institutional and retail investors, and an employee stock ownership plan completed on August 4, 2025 that transferred 2,894,406 shares (≈0.17% of issued capital) with a 72‑month lockup, and as of December 31, 2024 the company employed 2,647 people (an 11.35% decline) while generating revenue from products like Ansomone® and Anterferon®, diagnostics, peptide APIs and cosmetic lines, all backed by strategic partnerships, R&D platforms for precision oncology and genetic engineering, and ambitions for international expansion
Anhui Anke Biotechnology Co., Ltd. (300009.SZ): Intro
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) is a Chinese biopharmaceutical company founded in Hefei, Anhui Province on September 28, 2000. The company develops, manufactures and commercializes biologics and biopharmaceutical products, with activities spanning R&D, clinical development, manufacturing and commercialization. It became publicly listed on the Shenzhen Stock Exchange ChiNext board in 2009, accelerating capital access and market presence.- Founded: September 28, 2000 (Hefei, Anhui Province)
- Listing: Shenzhen Stock Exchange - ChiNext board (2009)
- Core focus: biologics, monoclonal antibodies, recombinant proteins, ADC collaboration
| Year / Metric | Revenue (CNY) | YoY Revenue Growth | Net Profit (CNY) | YoY Net Profit Growth | Employees (year-end) |
|---|---|---|---|---|---|
| 2016 (reported baseline) | ~852 million | - | ~197 million | - | - |
| 2017 | 1.10 billion | +29.09% | 278 million | +40.77% | - |
| 2022 | - | - | - | - | - |
| 2024 (as of Dec 31, 2024) | - | - | - | - | 2,647 (-11.35% vs 2023) |
| Strategic M&A / Licensing | 2022 acquisition: $50 million | - | 2024 licensing: ADC tech (EZWi‑Fit®) | - | - |
- 2000 - Company established in Hefei, Anhui Province.
- 2009 - Listed on Shenzhen Stock Exchange's ChiNext board, one of the early ChiNext listings.
- 2017 - Reported revenue of 1.10 billion CNY and net profit of 278 million CNY (29.09% and 40.77% YoY increases respectively).
- 2022 - Expanded pipeline via acquisition of a monoclonal antibody-specialized biotech for $50 million.
- 2024 - Entered licensing agreement with Shanghai Escugen Biotechnology Co., Ltd. to use the EZWi‑Fit® ADC platform for targeted antibody‑drug conjugate development.
- 2024 (Dec 31) - Workforce at 2,647 employees, down 11.35% year‑on‑year reflecting strategic optimization.
- Publicly traded entity on ChiNext (300009.SZ), with a shareholder base comprising institutional investors, retail investors and corporate stakeholders.
- Organizationally structured as a group with multiple R&D and manufacturing subsidiaries to cover discovery, development, CMC and commercialization.
- Governance follows PRC public company regulations and ChiNext disclosure requirements; strategic partnerships and licensing deals are used to augment in‑house capabilities.
- Mission: develop innovative biologics and biopharmaceutical therapies addressing unmet medical needs in oncology, immunology and other therapeutic areas.
- Strategic levers: internal R&D, targeted acquisitions (e.g., 2022 monoclonal antibody acquisition), external licensing (e.g., 2024 ADC platform), and scale‑up of manufacturing capacity.
- Discovery & Preclinical: in‑house teams and external collaborations screen and optimize biologic candidates (mAbs, recombinant proteins, ADCs).
- Clinical Development: conduct Phase I-III trials domestically and in selected international jurisdictions; leverage partnerships to share clinical risk and expertise.
- Manufacturing: operate GMP‑compliant production facilities for biologics; invest in capacity to support commercialization and contract manufacturing.
- Commercialization: sell marketed biologics through hospital channels, distributor networks and institutional tenders; pursue label expansions and lifecycle management.
- Product sales: core revenue from marketed biologic products (recombinant proteins, therapeutic antibodies).
- Licensing & collaboration income: upfronts, milestones and royalties from out‑licensing or in‑licensing technology platforms (e.g., EZWi‑Fit® ADC collaboration).
- Contract manufacturing and services: CMO/CMO‑like services to other biotech/pharma customers.
- Strategic M&A value creation: acquisitions to broaden pipeline and future revenue potential (2022 $50M acquisition example).
| Indicator | Value / Note |
|---|---|
| 2017 Revenue | 1.10 billion CNY |
| 2017 Net Profit | 278 million CNY |
| 2017 Revenue Growth | +29.09% YoY |
| 2017 Net Profit Growth | +40.77% YoY |
| 2022 Strategic Acquisition | $50 million (monoclonal antibody specialist) |
| 2024 Licensing | EZWi‑Fit® ADC platform with Shanghai Escugen Biotechnology Co., Ltd. |
| Employees (Dec 31, 2024) | 2,647 (-11.35% vs 2023) |
Anhui Anke Biotechnology Co., Ltd. (300009.SZ): History
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) is a Shenzhen-listed biopharmaceutical group with a history of technology-driven growth, an active employee ownership culture, and a shareholder mix that supports sustained R&D investment and market expansion. The company's governance and capital structure reflect both founder-led strategic direction and participation from institutional and retail investors. See more: Anhui Anke Biotechnology (Group) Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money- Listed on Shenzhen Stock Exchange (ticker: 300009.SZ).
- Founder and chairman Du Zhenghua is the largest shareholder and key strategic decision-maker.
- Diversified shareholder base: institutional investors, individual shareholders, and employee stock ownership plans.
- Ownership structure oriented to support long-term R&D and market expansion initiatives.
| Item | Detail |
|---|---|
| Listing | Shenzhen Stock Exchange - 300009.SZ |
| Latest employee stock transfer | Fourth ESOP completed on 4 Aug 2025 - 2,894,406 shares transferred (0.17% of issued capital) |
| ESOP duration | 72 months total, with five unlocking phases beginning 12 months after transfer announcement |
| Control | Founder/chairman Du Zhenghua - largest single shareholder (controls strategic direction) |
| Shareholder mix | Institutional investors, individual shareholders, employee-held shares |
Anhui Anke Biotechnology Co., Ltd. (300009.SZ): Ownership Structure
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) centers its corporate purpose on discovering, developing, manufacturing and marketing healthcare products that improve quality of life. The company's stated mission emphasizes innovation in novel drugs and therapies, adherence to international quality standards and ethical practices, customer-centric access to treatments, collaborative R&D and social and environmental responsibility.- Mission: Discover, develop, manufacture and market high‑quality healthcare products and services to improve human life.
- Core values: innovation, integrity, transparency, customer‑centricity, collaboration, social responsibility.
- R&D focus: novel biologics, innovative small molecules and technology platforms to address unmet medical needs.
| Item | Latest reported / Typical detail |
|---|---|
| Ticker | 300009.SZ |
| Corporate form | Publicly listed biotech company (A‑share) |
| Major shareholder types | State‑affiliated corporate investors, strategic corporate partners, institutional investors, retail shareholders |
| R&D intensity | High: significant proportion of revenue routinely reinvested into R&D (company emphasizes pipeline investment) |
| Primary revenue sources | Proprietary drug sales, contract manufacturing, licensing and collaboration income |
| Global partners / collaborations | Multiple licensing and co‑development agreements to accelerate novel therapies |
| Commitment to standards | Compliance with international quality systems and regulatory guidelines; emphasis on ethical business practices |
- How it makes money:
- Commercial sales of approved pharmaceuticals and biologics
- Contract development and manufacturing services (CDMO)
- Out‑licensing, milestone and royalty income from partners
- Collaborative R&D agreements and government / public health program contracts
- Business model enablers:
- Robust R&D pipeline and platform technologies
- Quality manufacturing capacity and regulatory compliance
- Partnerships to expand markets and accelerate development
Anhui Anke Biotechnology Co., Ltd. (300009.SZ): Mission and Values
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) operates an integrated biopharmaceutical value chain combining in-house research and development, GMP-compliant manufacturing, regulatory affairs and commercial distribution. Its stated mission emphasizes "innovative biological drugs and precision therapies to improve patient outcomes," while corporate values prioritize scientific integrity, quality compliance and expanding global partnerships. How It Works AnkeBio's operating model centers on vertically integrated capabilities that shorten time-to-market and capture greater margin across product life cycles:- Research & Development: internal discovery and development in genetic engineering, diagnostic reagents, precision oncology platforms and R&D on TCM-derived biologics.
- Manufacturing: multiple GMP-standard production lines for biologics and diagnostic kits, allowing scale-up of clinical and commercial batches.
- Commercialization: a national sales and distribution network that converts clinical approvals into hospital and retail coverage across China and select export markets.
- National-recognized enterprise technology center: central R&D hub for platform technologies and late-stage development.
- National-local joint engineering research center: focused on precise tumor treatment technologies and product engineering.
- Qualified scientific team: researchers in molecular biology, bioprocess engineering and clinical development supporting IND/CTA submissions.
- GMP compliance: production facilities designed and operated to meet Chinese GMP standards; capacity to produce sterile injectables, bulk biologics and diagnostic reagents.
- Quality systems: in-house QC, stability testing and batch release procedures aligned with regulatory expectations for domestic approvals and export dossiers.
- Domestic network: sales presence covering more than 30 provinces with over 40 regional offices and hospital account teams.
- International expansion: accelerating cooperation with overseas partners and distributors for select products and technologies.
- Licensing & alliances: engages in licensing, co-development and distribution agreements to broaden therapeutic and diagnostic offerings - including a 2024 licensing agreement with Shanghai Escugen Biotechnology Co., Ltd.
| Metric | Value / Note |
|---|---|
| Approximate annual revenue (most recent reporting year) | RMB 1.2 billion (approx.) |
| R&D investment | ~7-10% of revenue (company disclosure trend) |
| Employees | ~2,500 (R&D, manufacturing, commercial) |
| Regional offices | 40+ |
| Provinces covered | 30+ |
| GMP production sites | Multiple sites with sterile biologics and reagent production lines |
| Key technical platforms | National enterprise technology center; national-local joint engineering research center for precise tumor treatment |
| Notable 2024 collaboration | Licensing agreement with Shanghai Escugen Biotechnology Co., Ltd. |
- Product mix: revenues derived from marketed biologic therapeutics, diagnostic kits and licensed technologies; high-margin biologics and precision therapy products provide outsized contribution as they scale.
- Pipeline monetization: milestone payments, royalties and upfront license fees from strategic partnerships accelerate non-product revenue.
- Manufacturing leverage: internal GMP capacity reduces COGS for core products and enables toll manufacturing revenue streams.
- Genetic engineering programs: biologic therapeutics progressing through preclinical and clinical stages, leveraging in-house process development.
- Precision oncology: engineering and product development guided by the national-local joint research center to develop targeted tumor therapies and companion diagnostics.
- Diagnostic products: commercialized reagent lines supporting hospital diagnostics and screening-providing recurring consumables revenue.
- Licensing & co-development: recent deals (e.g., 2024 licensing with Shanghai Escugen) expand therapeutic indications and geographic reach.
- Internationalization: targeted partnerships and regulatory filings aimed at selected export markets to diversify revenue sources.
Anhui Anke Biotechnology Co., Ltd. (300009.SZ): How It Works
Anhui Anke Biotechnology Co., Ltd. (300009.SZ) operates as an integrated biopharmaceutical company that develops, manufactures and commercializes recombinant proteins, peptides, diagnostic reagents and related products. The company combines in-house R&D, GMP-compliant manufacturing, a national sales and distribution network and strategic licensing/partnership arrangements to convert scientific assets into commercial revenue.- Core product lines: recombinant human growth hormone (Ansomone®) and recombinant human interferon alpha 2b (Anterferon®).
- Adjunct portfolios: diagnostic kits, peptide active pharmaceutical ingredients (APIs), beauty care products and synthetic drugs.
- Commercial footprint: sales network covering more than 30 provinces across China and growing international distribution.
| Revenue Stream | Description | Role in Business Model |
|---|---|---|
| Recombinant biologics (Ansomone®, Anterferon®) | Monoclonal and recombinant protein therapeutics manufactured in-house under GMP | Primary revenue driver; high-margin product sales and hospital/clinic procurement |
| Diagnostic kits | In vitro diagnostics for clinical and point-of-care use | Stable recurring sales to laboratories and medical institutions |
| Peptide APIs & Synthetic drugs | Contract manufacturing and proprietary small-molecule/peptide products | Diversifies revenue, supports B2B and B2C channels |
| Beauty care products | Cosmeceutical formulations leveraging peptide/biotech ingredients | High-volume retail channel, brand-extension revenue |
| Licensing & strategic partnerships | Agreements to co-develop, license or commercialize technologies (e.g., Shanghai Escugen Biotechnology Co., Ltd., 2024) | Upfront, milestone and royalty streams; accelerates market access |
| Services & contract manufacturing | Custom manufacturing and technical services for third parties | Utilizes excess capacity and stabilizes cash flow |
- Sales & distribution mechanics: AnkeBio leverages a field sales force and distributor agreements to place products into hospitals, clinics, diagnostic labs and retail outlets across >30 provinces.
- R&D-to-revenue pipeline: sustained R&D investment leads to label-expansions, new product launches and lifecycle management that influence revenue and profit growth through new indications and formulations.
- Partnership monetization: strategic licensing deals (example: 2024 agreement with Shanghai Escugen Biotechnology Co., Ltd.) create additional channels for royalties, milestones and co-commercialization proceeds.
- Equity & employee alignment: AnkeBio has implemented employee stock ownership plans to align staff with long-term performance; the fourth plan was completed on August 4, 2025, transferring 2,894,406 shares (0.17% of total issued capital) into the plan account.
Anhui Anke Biotechnology Co., Ltd. (300009.SZ): How It Makes Money
Anhui Anke Biotechnology generates revenue primarily through development, manufacture and sales of biological products (vaccines, plasma derivatives, recombinant proteins), chemical pharmaceuticals and related diagnostic reagents, supported by an expanding innovative biopharma pipeline and commercial partnerships. Its vertically integrated model spans R&D, GMP manufacturing, distribution and licensing, enabling capture of value across product lifecycles.- Diverse product mix: legacy high-volume biologicals and growing high-margin innovative biologics and chemical drugs.
- Sales footprint: commercial network covering more than 30 Chinese provinces with accelerating international cooperation.
- Monetization levers: direct product sales, contract manufacturing (CMO), licensing/royalty income from partnerships, and government/public procurement contracts.
- R&D-driven value creation: new product launches and clinical-stage assets expected to lift unit economics and average selling prices.
| Metric | Most Recent Reported Value |
|---|---|
| Annual revenue (approx.) | RMB 2.5 billion |
| Net profit (approx.) | RMB 350 million |
| R&D spend (% of revenue) | ~9% (RMB ~225 million) |
| Employees | ~4,000 |
| Geographic sales coverage | 30+ provinces; exports to multiple markets |
- Pipeline commercialization: planned launches of innovative biologics and high-value chemical drugs projected to drive mid-to-high single-digit top-line CAGR over coming years.
- Margin expansion drivers: mix shift to higher-margin biologics, scale-up of proprietary products, and licensing/royalty income.
- International growth: leveraging export channels and clinical/registration progress to access new markets outside China.
Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.